Zinbryta (daclizumab) / Biogen, AbbVie  >>  Phase 3
Welcome,         Profile    Billing    Logout  

17 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zinbryta (daclizumab) / Biogen, AbbVie
SUSTAIN, NCT02881567 / 2016-002820-10: Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Terminated
3b
41
Europe, Canada, US
Daclizumab, BIIB019, Zinbryta
Biogen, AbbVie
Relapsing-Remitting Multiple Sclerosis (RRMS)
09/18
09/18
NCT00053976: Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

Completed
3
105
US
Daclizumab, Zenapax, methylprednisolone, Placebo
Dana-Farber Cancer Institute, National Cancer Institute (NCI)
Graft Versus Host Disease
11/03
11/04
NCT00048152: A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

Completed
3
539
US, Canada, Europe, RoW
Corticosteroids, Neoral, Zenapax, mycophenolate mofetil [CellCept]
Hoffmann-La Roche
Kidney Transplantation
03/06
03/06
TAXI, NCT00682292: Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk

Completed
3
227
Europe
Thymoglobulin (ATG), Thymoglobulin, Genzyme, Daclizumab, Zenapax, Roche
University Hospital, Lille, Erasme University Hospital
Renal Transplantation
11/06
11/06
MARSILEA, NCT00295594 / 2004-001617-34: Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.

Completed
3
627
Europe
tacrolimus, Prograf, FK506
Astellas Pharma Inc
Liver Transplantation
06/07
06/07
PANTERA, NCT00321074 / 2004-002924-16: Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts

Completed
3
101
Europe
TACROLIMUS, Prograf, FK506
Astellas Pharma Inc
LIVER TRANSPLANTATION
10/07
10/07
TWIST, NCT00296348 / 2005-001348-22: Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation

Completed
3
198
Europe, RoW
tacrolimus, Prograf, FK506, mycophenolate mofetil, MMF, daclizumab, steroids
Astellas Pharma Inc
Kidney Transplantation
02/08
02/08
NCT00195273: Study Evaluating Sirolimus in Kidney Transplant Recipients

Completed
3
61
Europe
sirolimus, cyclosporine, mycophenolate mofetil, corticosteroids, daclizumab
Wyeth is now a wholly owned subsidiary of Pfizer
Graft vs Host Disease, Kidney Transplantation
07/08
07/08
NCT00275509: Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Completed
3
56
US
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Johns Hopkins University
Kidney Failure, Chronic
06/10
06/10
NCT02686619: Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients

Completed
3
237
Europe
Cyclosporine, Neoral, Daclizumab, Zenapax, Mycophenoate Mofetil, CellCept, Prednisolone, Solupred, Sirolimus, Rapamycin
Hoffmann-La Roche
Renal Transplantation
01/11
01/11
NCT01064401 / 2009-012500-11: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Checkmark CMSC 2016
Jun 2016 - Jun 2016: CMSC 2016
Checkmark From SELECT and DECIDE trials in MS
Jun 2016 - Jun 2016: From SELECT and DECIDE trials in MS
Checkmark DECIDE; SELECT trilogy
More
Completed
3
1841
US, Canada, Europe, RoW
BIIB019 (Daclizumab High Yield Process), DAC HYP, Interferon beta-1a Placebo, Interferon beta-1a, Avonex, IFN β-1a, Daclizumab High Yield Process Placebo
Biogen, AbbVie
Relapsing-Remitting Multiple Sclerosis
03/14
07/14
NCT00468117: Efficacy of Islet After Kidney Transplantation

Completed
3
24
US, Canada
Islet transplantation, Antithymocyte Globulin, ATG, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes Mellitus
07/15
07/17
2006-006652-35: A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab,mycophenolate, ciclosporin and corticosteroids) in renal transplantation.

Completed
3
40
Europe
Rapamune, Zenapax, Cellcept, Sandimune, Not available, Ro 24-7375, Ro 106-1443, Rapamune, Zenapax, Cellcept, Sandimune, Rapamune, Zenapax, Cellcept, Sandimune
Queen Mary University of London
Renal Transplantation
 
01/12
NCT01462318 / 2010-023856-97: An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

Checkmark AAN 2015: Multiple sclerosis (OBSERVE)
Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (OBSERVE)
Checkmark ACTRIMS-ECTRIMS 2014: MS (OBSERVE; SELECTION)
Sep 2014 - Sep 2014: ACTRIMS-ECTRIMS 2014: MS (OBSERVE; SELECTION)
Completed
3
133
US, Europe
Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab), Daclizumab High Yield Process; DAC HYP
Biogen
Relapsing-Remitting Multiple Sclerosis
01/16
01/16
NCT01797965 / 2012-003176-39: Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

Terminated
3
1501
Europe, Canada, US, RoW
BIIB019 (Daclizumab), Daclizumab High Yield Process, DAC HYP
Biogen, AbbVie
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
09/18
09/18
NCT00181142: The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation

Completed
2/3
60
US
Zenapax
Johns Hopkins University
Patients Active and Listed for Lung Transplantation
12/04
12/04
2005-000904-15: Intervention with mycophenolate mofetil and daclizumab in patients with recently diagnosed type 1 diabetes mellitus

 
2/3
15
Europe
Mycophenolate mofetil, Daclizumab, MMF, DZB, CellCept, Zenapax, CellCept, Zenapax
George Washington University Biostatistics Center, NIDDK TYPE 1 DIABETES TRIALNET
Type 1 diabetes, recently diagnosed
 
11/08

Download Options